Celldex Therapeutics Financial Statements
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 29.89 0.00%
Celldex Therapeutics revenue and earnings
In fiscal 2025, Celldex Therapeutics generated $1.5 million in revenue, down 78.0% from fiscal 2024, its first annual decline since 2022. Celldex Therapeutics reported a net loss of $258.8 million, compared with a loss of $157.9 million a year earlier. Gross margin was 87.1% (down from 97.2%) and operating margin -18599.8%.
Diluted earnings per share came in at -$3.90. Over the last 5 fiscal years, CLDX's revenue has grown at a -26.9% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Celldex Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.54M | 7.02M | 6.88M | 2.36M | 4.65M | 7.42M | 3.57M | 9.54M | 12.74M | 6.79M |
| Revenue growth (YoY) | -77.99% | +1.99% | +192.02% | -49.32% | -37.30% | +107.61% | -62.54% | -25.15% | +87.78% | +23.83% |
| Cost of Revenue | 200.00K | 200.00K | 300.00K | 100.00K | 100.00K | 200.00K | 100.00K | 700.00K | 700.00K | 1.60M |
| Gross Profit | 1.34M | 6.82M | 6.58M | 2.26M | 4.55M | 7.22M | 3.47M | 8.84M | 12.04M | 5.19M |
| Operating Expenses | 288.71M | 201.90M | 161.13M | 117.49M | 75.79M | 70.57M | 58.50M | 165.27M | 133.57M | 138.10M |
| Research & Development | 245.07M | 163.55M | 118.01M | 82.26M | 53.31M | 42.53M | 42.67M | 66.45M | 96.17M | 102.73M |
| Operating Income | -287.37M | -195.08M | -154.54M | -115.23M | -71.24M | -63.35M | -55.03M | -156.44M | -121.53M | -132.92M |
| Pretax Income | -258.76M | -157.86M | -141.43M | -112.33M | -70.74M | -60.95M | -50.88M | -151.95M | -117.31M | -128.53M |
| Income Tax | 0 | 0 | 0 | — | -227.00K | -1.17M | — | -765.00K | -24.28M | — |
| Net Income | -258.76M | -157.86M | -141.43M | -112.33M | -70.51M | -59.78M | -50.88M | -151.18M | -93.03M | -128.53M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 | -2.02 | -3.51 | -14.48 | -10.86 | -18.99 |
| EPS (Diluted) | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 | -2.02 | -3.51 | -14.48 | -10.86 | -18.99 |
| Shares Outstanding (Basic) | 66.42M | 64.39M | 48.45M | 46.89K | 42.87K | 29.64K | 14.51K | 10.44K | 8.57M | 6.77M |
| Shares Outstanding (Diluted) | 66.42M | 64.39M | 48.45M | 46.89K | 42.87K | 29.64K | 14.51K | 10.44K | 8.57M | 6.77M |
| EBITDA | -283.99M | -191.90M | -151.53M | -112.34M | -68.17M | -59.42M | -50.17M | -152.86M | -117.11M | -129.82M |
| Gross Margin | 87.06% | 97.15% | 95.64% | 95.76% | 97.85% | 97.30% | 97.20% | 92.66% | 94.51% | 76.42% |
| Operating Margin | -18599.81% | -2778.89% | -2245.27% | -4889.01% | -1531.78% | -854.06% | -1540.19% | -1640.13% | -953.68% | -1958.68% |
| Net Margin | -16748.03% | -2248.76% | -2054.76% | -4765.59% | -1516.04% | -805.88% | -1423.96% | -1585.07% | -730.06% | -1894.05% |
This table shows 10 annual periods of Celldex Therapeutics's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow CLDX's reporting calendar. What is a income statement?